Testing a new drug for IgA kidney disease with high risk
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 3 trial tests sefaxersen to see if it slows kidney damage in people with primary IgA nephropathy (IgA kidney disease) who are at high risk of progression. It also checks how safe the drug is over the study period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary IgA kidney disease confirmed by a kidney biopsy within the last 10 years
- You have been on the highest tolerated ACE inhibitor or ARB dose for at least 90 days before screening (unless you can’t tolerate it)
- Your urine protein levels are high (from a 24-hour urine test) so you are considered at higher risk
- Your kidney filtering function (eGFR) is at least 20 (with diabetes ruled out; see questions below)
- You are up to date on certain meningitis, pneumonia, and Hib vaccines
- If you can become pregnant, you must use reliable birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests an experimental drug (HRS-5965) for people with IgA nephropathy (a kidney disease). It aims to find out if the drug can help reduce protein in the urine and protect kidney function. To join, you must have had a kidney biopsy showing IgA nephropathy within the past 8 years and have significant protein in your urine despite taking standard treatments.
This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.
This study tests an experimental drug called NTQ5082 for people with IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
This trial tests a new drug called mezagitamab for adults with IgA nephropathy, a kidney condition. The study aims to see if this drug can help reduce protein in the urine and preserve kidney function. You may be eligible if your kidney function is above a certain level and your urine protein is high enough.
Hear when a new Primary IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.